Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
It has not been established firmly whether dyslipidemia contributes independently to the progression of kidney disease. Lipid and lipoprotein parameters, including levels of total, HDL, and LDL cholesterol; triglycerides; lipoprotein(a); apolipoprotein A-IV; and the apolipoprotein E and A-IV polymorphisms, were assessed in 177 patients who had mostly mild to moderate renal insufficiency and were followed prospectively for up to 7 yr. Progression of kidney disease was defined as doubling of baseline serum creatinine and/or terminal renal failure necessitating renal replacement therapy. In univariate analysis, patients who reached a progression end point (n = 65) were significantly older and had higher serum creatinine and proteinuria as well as lower GFR and hemoglobin levels. In addition, baseline apolipoprotein A-IV and triglyceride concentrations were higher and HDL cholesterol levels were lower. Multivariate Cox regression analysis revealed that baseline GFR (hazard ratio 0.714; 95% confidence interval [CI] 0.627 to 0.814 for an increment of 10 ml/min per 1.73 m(2); P < 0.0001) and serum apolipoprotein A-IV concentrations (hazard ratio 1.062; 95% CI 1.018 to 1.108 for an increment of 1 mg/dl; P = 0.006) were significant predictors of disease progression. Patients with apolipoprotein A-IV levels above the median had a significantly faster progression (P < 0.0001), and their mean follow-up time to a progression end point was 53.7 mo (95% CI 47.6 to 59.8) as compared with 70.0 mo (95% CI 64.6 to 75.4) in patients with apolipoprotein A-IV levels below the median. For the apolipoprotein E polymorphism, only the genotype epsilon2/epsilon4 was associated with an increased risk for progression. In summary, this prospective study in patients with nondiabetic primary kidney disease demonstrated that apolipoprotein A-IV concentration is a novel independent predictor of progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00165.x · Cited by 667
Effects of hypertension and dyslipidemia on the decline in renal function
Mänttäri, M., Tiula, E., Alikoski, T., & Manninen, V. (1995) · Hypertension · doi:10.1161/01.hyp.26.4.670 · Cited by 229
Cited by
Fliser, D., Kollerits, B., Neyer, U., Ankerst, D. P., Lhotta, K., Lingenhel, A., Ritz, E., & Kronenberg, F. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080936 · Cited by 699
Self-citationNeutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease
Bolignano, D., Lacquaniti, A., Coppolino, G., Donato, V., Campo, S., Fazio, M. R., Nicocia, G., & Buemi, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03530708 · Cited by 561
Biomarkers in chronic kidney disease: a review
Fassett, R. G., Venuthurupalli, S. K., Gobe, G. C., Coombes, J. S., Cooper, M. A., & Hoy, W. E. (2011) · Kidney International · doi:10.1038/ki.2011.198 · Cited by 449
Biomarkers in chronic kidney disease, from kidney function to kidney damage
Lopez-Giacoman, S. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.57 · Cited by 392
Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease
Podkowińska, A., & Formanowicz, D. (2020) · Antioxidants · doi:10.3390/antiox9080752 · Cited by 356
Metadata
- Authors
- Boes, E., Fliser, D., Ritz, E., König, P., Lhotta, K., Mann, J. F. E., Müller, G. A., Neyer, U., Riegel, W., Riegler, P., & Kronenberg, F.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-02
- Volume
- 17
- Issue
- 2
- Pages
- 528-536
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2127906346
- Cited by
- 84
- References
- 2
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study. https://app.cochat.ai/papers/10.1681/asn.2005070733
- The paper
- Boes, E., Fliser, D., Ritz, E., König, P., Lhotta, K., Mann, J. F. E., Müller, G. A., Neyer, U., Riegel, W., Riegler, P., & Kronenberg, F. (2006). Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2005070733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.